Pharmaceutical firm can expand work as funds secured

Mironid, a Lanarkshire pharmaceutical firm, has raised £4.3 million in Series A funding to continue research and preclinical development programmes into degenerative kidney disease, major inflammatory disease and cancer.



The funding round was led by Epidarex Capital, a fund with offices in Edinburgh that partners with leading universities and research institutions to fund all areas of health science. The Scottish Investment Bank, on behalf of Scottish Enterprise, and the University of Strathclyde also participated in the round. 

Mironid, which specialises in cell signalling directed drug development, was spun out of University of Strathclyde in 2015. 

The firm develops proprietary drug candidate molecules by controlling the activity of key phosphodiesterase 4 (PDE4) enzymes. These enzymes decrease production of natural anti-inflammatory mediators and are thought to contribute to a number of inflammatory diseases. 

Commenting on the funding, Paul Rodgers, executive chairman at Mironid, highlighted the ambition and commitment of the founders of Mironid. 

“The funds raised will allow the rapid acceleration of the company’s programmes to enable further product pipeline development,” he said. 

While clinical trials remain years away Dr Rodgers said the funding would allow staff numbers to grow from seven to ten or 12 in the next year, ahead of a further round of funding. 

“The funding was critical to allow us to do what we need to do,” he added. “This is the first significant cash injection for us and we can really motor on from here.” 

We have endeavoured to provide Mironid with joined up support from early stage research, to company formation and now investment to help them scale up their operations.”

Find sciences jobs in Scotland